Salarius Pharmaceuticals Inc
NASDAQ:SLRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
Porsche Automobil Holding SE
OTC:POAHY
|
DE |
Salarius Pharmaceuticals Inc
Other Assets
Salarius Pharmaceuticals Inc
Other Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Salarius Pharmaceuticals Inc
NASDAQ:SLRX
|
Other Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Assets
$35.6B
|
CAGR 3-Years
3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Assets
$8.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
22%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Assets
$18.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Assets
$1.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
2%
|
CAGR 10-Years
36%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Salarius Pharmaceuticals Inc
Glance View
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company. The company is headquartered in Houston, Texas and currently employs 16 full-time employees. The company went IPO on 2015-01-29. In addition, the Company is also developing treatments for cancers caused by dysregulated gene expression. The firm is developing two classes of drugs that address gene dysregulation: epigenetic drugs and targeted protein degraders. The Company’s technologies have the potential to work in both liquid and solid tumors. The Company’s pipeline consists of two compounds: seclidemstat (SP-2577), which is a small molecule that inhibits the epigenetic enzyme lysine specific demethylase 1 (LSD1); SP-2577 uses a reversible mechanism to inhibit LSD1’s enzymatic and scaffolding properties and thereby treat and prevent cancer progression, and SP-3164, which is a cereblon binding molecular glue and has a development path in hematological cancer and potential in solid tumors.
